Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10676727
ABSTRACT:
The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.
REFERENCES:
patent: 4965155 (1990-10-01), Nishiguchi et al.
patent: 6380186 (2002-04-01), Howard
patent: 6403592 (2002-06-01), Howard
patent: 6423708 (2002-07-01), Gibbs et al.
patent: 2002/0049211 (2002-04-01), Sobolov-Javnes et al.
patent: 2002/0049214 (2002-04-01), Gibbs et al.
patent: 2002/0072519 (2002-06-01), Howard
patent: 2002/0091117 (2002-07-01), Howard
patent: 2002/0091118 (2002-07-01), Howard
patent: 2002/0091119 (2002-07-01), Howard
patent: 1-156752 (1989-06-01), None
patent: 1-172836 (1989-07-01), None
patent: 1-173065 (1989-07-01), None
Ma et al., J. Biol. Chem. 277(40), pp. 37235-37241 (Oct. 4, 2002); originally published in Press as doi:10.1074/jbc, M205932200 on Aug. 2, 2002.
Ma et al., The Journal of Clinical Investigation, 110(11), pp. 1651-1658 (Dec. 2002).
Roman et a., Farmatsevtichnii Zhurnal (2002) (3), 56-59 (abstract).
Abdel-Rahman et al., “Heterodiene Synthesis I Reaction of 5-Arylidenerhodanine Derivatives with 1-Morpholinocyclohexene Enamine”, Synthetic Communications 19(3&4) pp. 345-354 (1989).
Abdel-Rahman et al., “A Chemical Evidence Supporting the Formation of Dihydropyran Aducts from the Reaction of 5-Arylidenerhodanines with 1-Morpholonocyclohexene through zwitterionic Intermediate”, Afinidad L. 50(445), pp. 155-159 (1993).
Abdel-Rahman, “Dihydopyrans from the Heterodienic Reaction of 5-Arylidenerhodanine Derivatives with Isoprene”, Chem Paper 47(6) 385-387 (1993).
Cabantchik et al., “Chemical Probes for Anion Transporters of Mammalian Cell Membranes”, Invited Review The American Physiological Societypp. C803-C827 (1992).
Edwards et al., “Induction of a Glibenclamide-sensitive K-current by Modified of a Delayed Rectifier Channel in Rat Portal Vein and Insulinoma Cells” Br. J. Pharmacol, 110, 1280-1281 (1993).
El-Shafel et al., “Applications of Phase-Transfer Catalysis in Reactions with Rhodanine Derivatives”, Gazzetta Chimica Italiana, 120, pp. 197-201 (1990).
Gabriel et al., “Cystic Fibrosis Heterozygote Resistance to Cholera Toxin in the Cystic Fibrosis Mouse Model”, Science Vol. 266, pp. 107-109 (1994).
Gabriel et al., “A Novel Plant-Derived Inhibitor of cAMP-Mediated Fluid and Chloride Secretion” The American Physiological Society pp. G58-G63 (1999).
Galietta et al., “Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds”, J. Biological Chemistry vol. 276, No. 23 pp. 19723-19728 (Jun. 2001).
Gorbach et al., “Acute Undifferentiated Human Dxiarrhea in the Tropics”, The journal of Clinical Investigations vol. 50, pp. 881-889 (1971).
Grubb et al., “Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis” The American Physiology Society, Physiology Reviewsvol. 79 Suppl. S193-S214 (1999).
Gupta et al., “Synthesis and Fungitoxicity of Some 5-Substituted-3-Polynitrophenyl Rhodanines”, J. Indian Chem Soc. vol. LV, pp. 483-485. (1978).
Hongre et al., “Effects of Sulphonyllureas on camp-Stimulated CI- Transport Via the Cytic Fibrosis Gene Product in Human Epithelial Cells”, Pflugers Arch 426: 284-287 (1994).
Jayaraman et al., “Submucosal Gland Secretions in Airways From Cystic Fibrosis Patients Have Normal [Na+] and ph But Elevated Viscosity”, PNAS VO >98 No. 14 8119-8123 (Jul. 2001).
Khalil et al., “The Action of Arllamines on 3-Aryl-5-Arylmethylenerhodanines”, Revue Roumaine de Chimie 23, 6, pp. 935-941 (1978).
Khan et al., “Synthesis and Insecticidal Activity if 5-amino-7-arly-6-cyano-3-substitute-thiazolo [4,5-b]-2,3,4,7. . . ”, Indian Journal of Chemistry vol. 378 pp. 1069-1074 (1998).
Ladnaya et al., “Synthesis and Properties of Thiazolidons-4 Obtained From Phenamine II. Thiasolidindions-2,4”, Luov Medical Institute pp. 37-41.
Lohi et al., “Upregulation of CFTR Expression but not SLC26A3 and SLC9A3 in Ulcerative Colitis”, American Journal Physio Gastroinest Liver Physiology 283 G567-G575(2002).
Makhlouf et al., “New Antomicrobial Rhodanines” Pharmazie. 51, 430-431 (1996).
McDonough et al., “Novel Pore-Lining Residues in CFTR That Govern Permeation and Open-Channel Block” Neuron vol. 13, pp. 623-634 (Sep. 1994).
Noone et al., “CFTR-Opathies′:Disease Phenotypes Associated with Cystic Fibrosis Transmembrarie Regulator Gene Mutations” Respir Res. 2:328-332 (2001).
Oi et al., “Identification in Traditional herbal Medications and Confirmation by Synthesis of Factors that Inhibit Cholera Toxin-Induced Fluid Accumulation”, PNAS vol. 99 No. 5 3042-3046 (Mar. 2002).
Omar et al., “The Role of Substituents at Position03 on the Mode of Cleavage of 5-Arylmethylene-2, 4-dioxothiazolidines”, Journal f. prakt. Chemie. Band 331, Heft 3, 1989, S393-S398 (1989).
Pilewski et al., “Role of CFTR in Airway Disease” Physiological Reviewsvol. 79, Suppl No. 1, pp. S215-S255 (Jan. 1999).
Rabe et al., “Cl-Channel Inhibition by Glibenclamide is Not Specific for the CFTR-type CI- Channel”, Pflugers Arch-Eur J. Physiol 429: 659-662 (1995).
Rasola et al., “Volume-Sensitive Chloride Currents in Four Epithelial Cell Lines Are Not Directly Correlated to the Expression of the MDR-1 Gene”, The J. Biol Chem. vol. 269. No. 2 pp. 1432-1436 (Jan. 1994).
Richardson et al., “Studies on the Genetic and Cellular Control of Sensitivity to Enterotoxins in the Sealed Adult Mouse Model”, Infection and Immunity vol. 54, No. 2, pp. 522-528 (Nov. 1986).
Schultz et al., “Pharmacology of CFTR Chloride Channel Activity”, Physiological Reviewsvol. 79, Suppl No. 1, pp. S109-S144 (Jan. 1999).
Sheppard et al., “Effect of ATP-sensitive K+ Channel regulators on Cystic Fibrosis Transmembrane Conductance Regulator Chloride Currents”, J. Gen Physiol. pp. 573-591 (Oct. 1992).
Tejchman et al., “Introduction of Selenium to Hetreocyclic Compounds. Part VII. Synthesis of 3-Alkyl-5-5-benzylidene- and . . . ”, Polish j. Chem., 73, 1315-1322 (1999).
Tejchman et al., “Introduction of Selenium to Hetreocyclic Compounds. Part VI. Synthesis of 3-Arly-5-benzylidene- and . . .”, Polish j. Chem., 70, 1124-1134 (1996).
Tiwari et al., “Synthesis and Fungiicidal Activity of Some 3,7-diaryl-6-cyanorhodanino[4,5-b]-pyridin-5. . . ”, Indian Journal of Chemistry vol. 28B pp. 796-798 (1989).
Wong et al., “CFTR Gene and Male Fertility”, Molecular Human Reproduction vol. 4, No. 2 pp. 107-110 (1998).
Yadav et al., “Synthesis and Fungitoxicity of Rationally Designed Thiazolo-1,3-dithiins, -thiazines , and oxathiins” J. Agric. Food Chem 40, pp. 1214-1216 (1992).
Yamada et al., “Dai-2-bu”, Utsunomiya Daigaku Kyoikugakubu Kiyo,34:33-41 (1983).
Yamazaki et al., “Inhibitory Effects of Glibenclamide on Cystic Fibrosis Transmembrane Regulator, Swelling-Activated, and Ca2+-Activated Cl- Channels in Mammalian Cardiac Myocytes” Circulation Research vo. 81(1) pp. 101-109. (Jul. 1997).
Appendix C—Thiazolidinone Chemical Structure Search (Identified References) pp. 1-70 (2002).
Memorandum Regarding Compound Collections, Dated May 15, 2003.
Database HCAPLUS on STN Online, No. 2002:932809, Ma et al., “Thiazolidinone CFTR Inhibitor Identified by High-Throughput Screening Blocks Cholera Toxin-Induced Intestinal Fluid Secretion,” abstract, Journal of Clinical Investigation, 2002, vol. 110, N
Ma Tonghui
Verkman Alan
Seed IP Law Group PLLC
Spivack Phyllis G.
The Regents of the University of California
LandOfFree
Methods of treating secretory diarrhea using cystic fibrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating secretory diarrhea using cystic fibrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating secretory diarrhea using cystic fibrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3824895